← All trials
NCT00780598
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2009
- Primary completion
- Mar 1, 2011
- Completion date
- Mar 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 76
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Chroma TherapeuticsLead sponsor
- Duke UniversityOverall official - principal investigator
- University of ChicagoOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- Yeshiva UniversityOverall official - principal investigator
- Georgetown UniversityOverall official - principal investigator
- Monter Cancer CenterOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- Froedtert Memorial Lutheran HospitalOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- IQVIACollaborator
- Washington University in St. LouisOverall official - principal investigator
- Rutgers UniversityOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Erasmus University RotterdamOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- University of MelbourneOverall official - principal investigator
- Ben Gurion UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.